Catalog No. |
TD-HW630026 |
Species reactivity |
Human |
Applications |
Research Grade Biosimilar |
Isotype |
Fusion - [CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)]2 - IGHG1 Fc (Fragment constant) |
Expression system |
Mammalian Cells |
Target |
CD80, BB1, T-lymphocyte activation antigen CD80, CD28LG, B7, CD28LG1, LAB7, Activation B7-1 antigen, CTLA-4 counter-receptor B7.1, BU63, B70, CD28LG2, CTLA-4 counter-receptor B7.2, Activation B7-2 antigen, T-lymphocyte activation antigen CD86, CD86, FUN-1 |
Endotoxin level |
Please contact the lab for this information. |
Purity |
>95% purity as determined by SDS-PAGE. |
Purification |
Protein A/G, purified from cell culture supernatant. |
Accession |
P33681 & P42081 |
Form |
Liquid |
Storage buffer |
0.01M PBS,pH7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names |
BMS-224818,LEA29Y,CAS:706808-37-9 |
Background |
Belatacept (BMS 224818) is a selective T-cell costimulation blocker and a costimulator of the CD28-CD80/86 pathway. Belatacept binds to the CD 80/86 ligand and inhibits CD-28-mediated T cell costimulation and IFN-γ production. Belatacept can be used in studies of immunosuppression in organ transplantation. |
Note |
For research use only. Not for use in clinical or therapeutic applications. |